Macular Edema Treatment Market Shows Boosted Growth Rate 2018-2026 Estimated by Global Top Players
Macular edema is the
condition characterized by abnormal leakage and accumulation of fluid
that forms blister in the layer of macula. The macula is an
oval-shaped pigmented area near the center of retina. This blister
causes the macula to swell and thicken that causes distortion of
vision. Although macular edema has numerous causes, the most common
cause is diabetes. Other causes include, age-related macular
degeneration, replacement of lenses in treatment of cataract, chronic
uveitis and intermediate uveitis, blockage of vein in the retina, and
congenital diseases including retinitis pigmentosa and retinoschisis.
Symptoms of macular edema include blurry or wavy vision near or in
the center of field of vision. The disease is diagnosed by performing
tests such as visual acuity test, dilated eye exam, fluorescein
angiogram, optical coherence tomography, and Amsler grid.
Get Exclusive
Sample Report at: http://bit.ly/2IgbA7y
Macular Edema
Treatment Market: Drivers
Increasing number of
pipeline studies is expected to drive the macular edema treatment
market growth. For instance, in April 2018, University of California,
Davis, in collaboration with IRIDEX Corporation, initiated phase 3
clinical trial for Micropulse Laser Treatment to evaluate micropulse
for suppression of diabetic macular edema (pulse). The primary aim of
the study is to determine whether the micropulse laser treatment in
eyes with good visual acuity will improve or stabilize vision loss
due to the complications of diabetic macular edema. The study is
expected to be completed by December 2020.
Furthermore,
increasing approval for new diabetic macular edema (DME) therapies is
expected to propel growth for the macular edema treatment market. For
instance, in March 2018, U.S. Food and Drug Administration (FDA)
approved Lucentis (ranibizumab injection) 0.3 mg prefilled syringe
(PFS) for diabetic macular edema and diabetic retinopathy. Lucentis
0.3 mg PFS is the first syringe prefilled with an anti-vascular
endothelial growth factor (VEGF) agent. Moreover, in 2016 U.S.FDA
approved Lucentis 0.5 mg PFS, which is intended for use in the
treatment of neovascular (wet) age-related macular degeneration
(AMD), macular edema following retinal vein occlusion (RVO), and
myopic choroidal neovascularisation (mCNV).
However, lack of
awareness of diabetic eye diseases among the patients with diabetes
is expected to hinder the macular edema treatment market growth.
Macular Edema
Treatment Market: Regional Analysis
On the basis of
region, the global macular edema treatment market is segmented into
North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa.
North America is
expected to account for the largest market share in the macular edema
treatment market, owing to increasing prevalence of diabetic macular
edema in this region. For instance, according to American Journal of
Managed Care (AJMC), in 2016, the prevalence rate of diabetic macular
edema was 45.3% in North America.
Moreover, in 2013,
as per National Center for Biotechnology Information (NCBI), around
98 million individuals reported for diabetic retinopathy (DR) and 21
million individual reported for diabetic macular edema (DME)
worldwide.
Furthermore,
increasing product approvals for the treatment of macular edema is
expected to boost growth of the macular edema treatment market in
Europe. For instance, in 2015, the European Commission approved Eylea
(aflibercept) for the treatment of patients with macular edema
secondary to retinal vein occlusion. Bayer HealthCare and Regeneron
collaborated to develop Eylea. Bayer HealthCare has exclusive
marketing rights to the product outside the U.S.
Ask For Discount
Before Purchasing This Business Report @ http://bit.ly/31wHqo1
Key players
operating in the macular edema treatment market include, Novartis
International AG, F. Hoffmann-La Roche Ltd, Regeneron
Pharmaceuticals, Inc., Pfizer Inc. Bayer AG, Aerpio Therapeutics,
Inc., Biomar Microbial Technologies, Antisense Therapeutics Limited,
Coherus BioSciences, and Bausch & Lomb Incorporated.
Macular Edema
Treatment Market Taxonomy
By Disease Type
Diabetic Macular
Edema
Cystoid Macular
Edema
By Drug Class
Anti-Vascular
endothelial growth factor (VEGF) injections
Avastin
Eylea
Lucentis
Anti-inflammatory Medication
Nonsteroidal
anti-inflammatory drugs (NSAIDs)
Corticosteroid
Ozurdex
Retisert
Iluvien
By End User
Hospitals
Ophthalmic
Clinics
Research
Institutes
By Region
North America
Europe
Asia Pacific
Latin America
Middle East
Africa
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment